31 related articles for article (PubMed ID: 38508094)
21. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
22. Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy.
Park Y; Kim MJ; Choi Y; Kim NH; Kim L; Hong SPD; Cho HG; Yu E; Chae YK
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347071
[TBL] [Abstract][Full Text] [Related]
23. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
[TBL] [Abstract][Full Text] [Related]
25. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].
Huang C; Yang X
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):777-783. PubMed ID: 34802209
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
27. Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy.
Luan F; Wang J; Liu L; Liu B; Li F; Zhao J; Lai J; Jiang F; Xu W; Zhang Z; Ran P; Shu Y; Yang Z; Fu G
Int Immunopharmacol; 2024 Apr; 131():111823. PubMed ID: 38508094
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
29. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
Miyawaki T; Naito T; Doshita K; Kodama H; Mori M; Nishioka N; Iida Y; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Kenmotsu H; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
Thorac Cancer; 2022 Jul; 13(14):2064-2074. PubMed ID: 35698259
[TBL] [Abstract][Full Text] [Related]
30. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
31. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
